scout
|Articles|December 12, 2014

Fulvestrant as First-Line Treatment for Advanced Breast Cancer

John F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

Clinical Pearls

John F. R. Robertson, MD, professor of surgery, faculty of medicine & health sciences, The University of Nottingham, United Kingdom, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.

  • 20-25 years ago, the average survival among patients with advanced breast cancer was 24 months. Now, it is 54.1 months.
  • Overall survival was 5.7 months higher with fulvestrant compared with anastrozole.
  • Benefit for fulvestrant over anastrozole was consistent across subgroups.

<<<

Go back to the SABCS conference page

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!

Related Content

Latest CME

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society
Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Marla D. Lipsyc-Sharf, MD; Ashley Frith, MD

View more
The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference
Video

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

View more
43rd Annual Miami Breast Cancer Conference®
In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Register now!
Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer
Video

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

View more
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

View more
Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment
Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

View more
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

View more
Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care
Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

View more
Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation
Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

View more
Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment
Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

View more
Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer
Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

View more
Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®
Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

View more
Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates
Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

View more
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

View more
Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment
Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

View more